-
Something wrong with this record ?
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network
H. Ludwig, E. Terpos, N. van de Donk, MV. Mateos, P. Moreau, MA. Dimopoulos, M. Delforge, P. Rodriguez-Otero, J. San-Miguel, K. Yong, F. Gay, H. Einsele, R. Mina, J. Caers, C. Driessen, P. Musto, S. Zweegman, M. Engelhardt, G. Cook, K. Weisel, A....
Language English Country England, Great Britain
Document type Journal Article, Review, Research Support, Non-U.S. Gov't
NLK
ProQuest Central
from 2000-09-01 to 2 months ago
Nursing & Allied Health Database (ProQuest)
from 2000-09-01 to 2 months ago
Health & Medicine (ProQuest)
from 2000-09-01 to 2 months ago
Public Health Database (ProQuest)
from 2000-09-01 to 2 months ago
- MeSH
- Interleukin 1 Receptor Antagonist Protein therapeutic use MeSH
- Immunotherapy, Adoptive adverse effects MeSH
- Consensus MeSH
- Humans MeSH
- Multiple Myeloma * drug therapy MeSH
- Antibodies, Bispecific * adverse effects MeSH
- Cytokine Release Syndrome etiology prevention & control drug therapy MeSH
- T-Lymphocytes MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
T-cell redirecting bispecific antibodies (BsAbs) and chimeric antigen receptor T cells (CAR T cells) have revolutionised multiple myeloma therapy, but adverse events such as cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome (ICANS), cytopenias, hypogammaglobulinaemia, and infections are common. This Policy Review presents a consensus from the European Myeloma Network on the prevention and management of these adverse events. Recommended measures include premedication, frequent assessing for symptoms and severity of cytokine release syndrome, step-up dosing for several BsAbs and some CAR T-cell therapies; corticosteroids; and tocilizumab in the case of cytokine release syndrome. Other anti-IL-6 drugs, high-dose corticosteroids, and anakinra might be considered in refractory cases. ICANS often arises concomitantly with cytokine release syndrome. Glucocorticosteroids in increasing doses are recommended if needed, as well as anakinra if the response is inadequate, and anticonvulsants if convulsions occur. Preventive measures against infections include antiviral and antibacterial drugs and administration of immunoglobulins. Treatment of infections and other complications is also addressed.
Cancer Center Clinica Universidad de Navarra Pamplona Spain
Centro de investigación biomédica en red de Oncologia Pamplona Spain
Centro de Investigación Medica Aplicada Pamplona Spain
Department of Hematology Amsterdam UMC VU University Amsterdam Netherlands
Department of Hematology Ankara University Ankara Türkiye
Department of Hematology CHU de Liège Liège Belgium
Department of Hematology University Hospital of Nantes Nantes France
Department of Internal Medicine University Hospital Würzburg Germany
Department of Medicine Clinic Ottakring Wilhelminen Cancer Research Institute Vienna Austria
Department of Oncology and Hematology Kantonsspital St Gallen St Gallen Switzerland
Division of Hematology University of Leuven Leuven Belgium
Erasmus MC Cancer Institute and Erasmus University of Rotterdam Rotterdam Netherlands
Instituto de Investigación Sanitaria de Navarra Pamplona Spain
KG Jebsen Center for B Cell Malignancies University of Oslo Oslo Norway
Oslo Myeloma Center Department of Hematology Oslo University Hospital Oslo Norway
Unit of Hematology and Stem Cell Transplantation AOUC Policlinico Bari Italy
Universitätsklinikum Hamburg Eppendorf Medizinische Klinik und Poliklinik Hamburg Germany
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23011139
- 003
- CZ-PrNML
- 005
- 20230801132830.0
- 007
- ta
- 008
- 230718s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/S1470-2045(23)00159-6 $2 doi
- 035 __
- $a (PubMed)37269857
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Ludwig, Heinz $u Department of Medicine, Clinic Ottakring, Wilhelminen Cancer Research Institute, Vienna, Austria. Electronic address: heinz.ludwig@extern.gesundheitsverbund.at
- 245 10
- $a Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network / $c H. Ludwig, E. Terpos, N. van de Donk, MV. Mateos, P. Moreau, MA. Dimopoulos, M. Delforge, P. Rodriguez-Otero, J. San-Miguel, K. Yong, F. Gay, H. Einsele, R. Mina, J. Caers, C. Driessen, P. Musto, S. Zweegman, M. Engelhardt, G. Cook, K. Weisel, A. Broijl, M. Beksac, J. Bila, F. Schjesvold, M. Cavo, R. Hajek, C. Touzeau, M. Boccadoro, P. Sonneveld
- 520 9_
- $a T-cell redirecting bispecific antibodies (BsAbs) and chimeric antigen receptor T cells (CAR T cells) have revolutionised multiple myeloma therapy, but adverse events such as cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome (ICANS), cytopenias, hypogammaglobulinaemia, and infections are common. This Policy Review presents a consensus from the European Myeloma Network on the prevention and management of these adverse events. Recommended measures include premedication, frequent assessing for symptoms and severity of cytokine release syndrome, step-up dosing for several BsAbs and some CAR T-cell therapies; corticosteroids; and tocilizumab in the case of cytokine release syndrome. Other anti-IL-6 drugs, high-dose corticosteroids, and anakinra might be considered in refractory cases. ICANS often arises concomitantly with cytokine release syndrome. Glucocorticosteroids in increasing doses are recommended if needed, as well as anakinra if the response is inadequate, and anticonvulsants if convulsions occur. Preventive measures against infections include antiviral and antibacterial drugs and administration of immunoglobulins. Treatment of infections and other complications is also addressed.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a mnohočetný myelom $x farmakoterapie $7 D009101
- 650 12
- $a protilátky bispecifické $x škodlivé účinky $7 D018033
- 650 _2
- $a syndrom uvolnění cytokinů $x etiologie $x prevence a kontrola $x farmakoterapie $7 D000080424
- 650 _2
- $a antagonista receptoru pro interleukin 1 $x terapeutické užití $7 D053590
- 650 _2
- $a konsensus $7 D032921
- 650 _2
- $a imunoterapie adoptivní $x škodlivé účinky $7 D016219
- 650 _2
- $a T-lymfocyty $7 D013601
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Terpos, Evangelos $u Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
- 700 1_
- $a van de Donk, Niels $u Department of Hematology, Amsterdam UMC, VU University, Amsterdam, Netherlands
- 700 1_
- $a Mateos, Maria-Victoria $u Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Centro de Investigación del Cancer, Salamanca, Spain
- 700 1_
- $a Moreau, Philippe $u Department of Hematology, University Hospital of Nantes, Nantes, France
- 700 1_
- $a Dimopoulos, Melitios-Athanasios $u Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
- 700 1_
- $a Delforge, Michel $u Division of Hematology, University of Leuven, Leuven, Belgium
- 700 1_
- $a Rodriguez-Otero, Paula $u Cancer Center Clinica Universidad de Navarra, Pamplona, Spain; Centro de Investigación Medica Aplicada, Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain; Centro de investigación biomédica en red de Oncologia, Pamplona, Spain
- 700 1_
- $a San-Miguel, Jesús $u Cancer Center Clinica Universidad de Navarra, Pamplona, Spain; Centro de Investigación Medica Aplicada, Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain; Centro de investigación biomédica en red de Oncologia, Pamplona, Spain
- 700 1_
- $a Yong, Kwee $u University College London Cancer Institute, London, UK
- 700 1_
- $a Gay, Francesca $u Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Torino, Italy
- 700 1_
- $a Einsele, Hermann $u Department of Internal Medicine, University Hospital Würzburg, Germany
- 700 1_
- $a Mina, Roberto $u Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Torino, Italy
- 700 1_
- $a Caers, Jo $u Department of Hematology, CHU de Liège, Liège, Belgium
- 700 1_
- $a Driessen, Christoph $u Department of Oncology and Hematology, Kantonsspital St Gallen, St Gallen, Switzerland
- 700 1_
- $a Musto, Pellegrino $u Department of Precision and Regenerative Medicine and Ionian Area, Aldo Moro University School of Medicine, Bari, Italy; Unit of Hematology and Stem Cell Transplantation, AOUC Policlinico, Bari, Italy
- 700 1_
- $a Zweegman, Sonja $u Department of Hematology, Amsterdam UMC, VU University, Amsterdam, Netherlands
- 700 1_
- $a Engelhardt, Monika $u Department of Hematology, Oncology and Stem Cell Transplantation, Clinical Cancer Research Group, Universitätsklinikum Freiburg, Freiburg, Germany
- 700 1_
- $a Cook, Gordon $u Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trial Research, University of Leeds, Leeds, UK
- 700 1_
- $a Weisel, Katja $u Universitätsklinikum Hamburg-Eppendorf, Medizinische Klinik und Poliklinik, Hamburg, Germany
- 700 1_
- $a Broijl, Annemiek $u Erasmus MC Cancer Institute & Erasmus University of Rotterdam, Rotterdam, Netherlands
- 700 1_
- $a Beksac, Meral $u Department of Hematology, Ankara University, Ankara, Türkiye
- 700 1_
- $a Bila, Jelena $u Clinic of Hematology, University Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
- 700 1_
- $a Schjesvold, Fredrik $u Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway; KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway
- 700 1_
- $a Cavo, Michele $u IRCCS Azienda Ospedaliero-Universitaria di Bologna, SeràgnoliIstituto di Ematologia, Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy
- 700 1_
- $a Hajek, Roman $u Department of Hemato-Oncology, University Hospital Ostrava & Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Touzeau, Cyrille $u Department of Hematology, University Hospital of Nantes, Nantes, France
- 700 1_
- $a Boccadoro, Mario $u Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Torino, Italy
- 700 1_
- $a Sonneveld, Pieter $u Erasmus MC Cancer Institute & Erasmus University of Rotterdam, Rotterdam, Netherlands
- 773 0_
- $w MED00011558 $t The Lancet. Oncology $x 1474-5488 $g Roč. 24, č. 6 (2023), s. e255-e269
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37269857 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230718 $b ABA008
- 991 __
- $a 20230801132827 $b ABA008
- 999 __
- $a ok $b bmc $g 1963501 $s 1197404
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 24 $c 6 $d e255-e269 $e - $i 1474-5488 $m Lancet oncology $n Lancet Oncol. $x MED00011558
- LZP __
- $a Pubmed-20230718
